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Chronically infected hepatitis C individuals commonly exhibit hepatic intracellular lipid 26 
accumulation, termed steatosis. Hepatitis C virus (HCV) infection perturbs host lipid 27 
metabolism through both cellular and viral-induced mechanisms, with the viral core 28 
protein playing an important role in steatosis development. We have recently identified a 29 
liver protein, the cell death-inducing DFFA-like effector B (CIDEB), as a HCV entry host 30 
dependence factor that is downregulated by HCV infection in a cell culture model. Here, 31 
we investigate the biological significance and molecular mechanism of this 32 
downregulation. HCV infection in a mouse model downregulated CIDEB in the liver 33 
tissue, and knockout of CIDEB gene in a hepatoma cell line results in multiple aspects 34 
of lipid dysregulation that can contribute to hepatic steatosis, including reduced 35 
triglyceride secretion, lower lipidation of very low density lipoproteins, and increased 36 
lipid droplet (LD) stability. The potential link between CIDEB downregulation and 37 
steatosis is further supported by the requirement of HCV core and its LD localization for 38 
CIDEB downregulation, which utilize a proteolytic cleavage event that is independent of 39 
the cellular proteasomal degradation of CIDEB.   40 
 41 
IMPORTANCE Our data demonstrate that HCV infection of human hepatocytes in vitro 42 
and in vivo results in CIDEB downregulation via a proteolytic cleavage event. Reduction 43 
of CIDEB protein levels by HCV or gene-editing in turn leads to multiple aspects of lipid 44 
dysregulation including LD stabilization. As such, CIDEB downregulation may contribute 45 





Hepatitis C virus (HCV) is a positive-strand RNA virus and a significant human 49 
pathogen. Chronic HCV infection causes liver complications such as steatosis, cirrhosis, 50 
and hepatocellular carcinoma. The arrival of new direct-acting antivirals (DAAs) has 51 
resulted in markedly improved virologic response in patients with access to these new 52 
drugs, but the high cost of the new therapy and the low diagnosis rate of HCV-infected 53 
individuals present new challenges for hepatitis C management (1). Furthermore, 54 
chronic liver damage can persist even after the infection has been cleared, so HCV 55 
pathogenesis remains an area of research highly significant for human health. 56 
 57 
The HCV life cycle and pathogenesis are intimately linked to host lipid metabolism (2). 58 
On one hand, lipids are involved in multiple stages of the infection cycle. HCV virions 59 
are assembled on lipid droplets (LDs) (3) and associated with host lipoproteins to form 60 
lipo-viral-particles (LVP) for infection (4); the productive entry of HCV is aided by several 61 
molecules involved in lipid uptake (5-7); replication of HCV genome critically depends 62 
on a lipid kinase (8, 9) and is regulated by lipid peroxidation (10). On the other hand, 63 
HCV infection profoundly disturbs lipid metabolism pathways (11). HCV patients exhibit 64 
enhanced lipogenesis (12), consistent with in vitro results showing that HCV infection 65 
upregulates genes encoding sterol regulatory element binding protein-1c (SREBP-1c) 66 
and fatty acid synthase (FASN), both important for the intracellular lipid synthesis 67 
pathway (13-16). More recently, the 3’-UTR of HCV was shown to, upon binding of 68 
DDX3, activate IκB kinase-α and trigger biogenesis of LDs (17). Consequently, liver 69 
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steatosis, the intracellular accumulation of lipids, is a common histological feature of 70 
chronic hepatitis C patients, especially in those with genotype 3 infection (18, 19). The 71 
mechanisms of viral-induced steatosis may involve both increased lipogenesis and 72 
reduced lipolysis and secretion (20, 21). The expression of HCV core protein was 73 
shown to recapitulate HCV-induced steatosis in a transgenic mouse model (22, 23) and 74 
the localization of core protein to LDs may be important for intracellular LD 75 
accumulation and steatosis induction (24-26).  76 
 77 
The cell death-inducing DFFA-like effector (CIDE) family proteins, CIDEA, CIDEB and 78 
CIDEC/ fat-specific protein 27 (Fsp27), were originally identified using a bioinformatics 79 
approach based on their homology to the N-terminal domain of DNA fragmentation 80 
factors (27). While CIDEA and CIDEC are more widely expressed, CIDEB is mostly 81 
expressed in liver cells (27) and induced during hepatic differentiation of stem cells (28, 82 
29). Although these proteins can induce cell death when overexpressed (27, 30, 31), 83 
gene knockout (KO) experiments in mice indicate that their function relates mostly to 84 
lipid metabolism in vivo (32-34).  A role of CIDEB in very-low-density lipoprotein (VLDL) 85 
lipidation, VLDL transport, and cholesterol metabolism has been reported in non-86 
primate cell culture models (34-36). We previously characterized a role of CIDEB in a 87 
late step of HCV entry into hepatocytes (29). In this study, we investigate the molecular 88 
mechanism and biological consequence of HCV-induced downregulation of CIDEB. We 89 
demonstrate that CIDEB protein is normally regulated through the ubiquitin-mediated 90 
proteasome pathway and that HCV infection further downregulates CIDEB by inducing 91 
CIDEB protein degradation, most likely through proteolytic cleavage. This HCV-92 
5 
 
mediated degradation of CIDEB requires the expression of HCV core, and 93 
downregulation of CIDEB protein was observed in a HCV-infected humanized mouse 94 
model. In addition, we demonstrate that gene knockout of CIDEB in a human hepatoma 95 
cell line reduces the secretion of triglycerides (TGs) and stabilizes cytoplasmic LDs in a 96 
manner similar to HCV infection. Core-dependent CIDEB downregulation in vivo may 97 
contribute to hepatic steatosis in the setting of HCV infection.  98 
 99 
MATERIALS AND METHODS 100 
Antibodies, compounds, and inhibitors. The following antibodies and chemicals were 101 
used in this study: anti-JFH-1 core and NS3 (BioFront Technologies Inc., FL); anti-102 
CIDEB, GAPDH, Ku80 (Santa Cruz Biotechnology, TX); anti-DENV-NS3 (Genetex, CA); 103 
FITC and TRITC conjugated anti-rabbit and anti-mouse IgGs (Sigma Aldrich, MO); oleic 104 
acid (OA), Oil Red O (ORO), cyclohexamide (CHX), Triacsin C (TriC), PF-429242 105 
(Sigma Aldrich, MO); and MG132 (EMD-Millipore, MA).  106 
 107 
Cell culture and HCVcc Infection. Huh-7.5 cells were provided by Dr. Charles Rice 108 
(Rockefeller University) and Apath LLC (NY). Generation of the CIDEB knockdown and 109 
knockout cell lines have been previously described (29). FLAG-CIDEB stable cells were 110 
generated using a human immunodeficiency virus (HIV)-based lentiviral vector 111 
expressing FLAG-CIDEB cDNA. Briefly, we transduced Huh-7.5 CIDEB KO cells with 112 
pHIV-7-IRES-FLAG-CIDEB, selected stable populations with 1.2µg/mL puromycin for 113 
three weeks then obtained single cell clones. For genotype 2 HCVcc infection, cells 114 
were inoculated with either wild type JFH-1 or several high titer variants: JFH-1/Ad16 115 
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(provided by Dr. Guangxiang Luo, University of Alabama at Birmingham), Mut4-6, and 116 
JLSO-III (37, 38) for 6-8 hours at 37°C, followed by three PBS washes before being 117 
changed into fresh media. The cell lines harboring infection by genotype 3 viruses have 118 
been described previously (39).  119 
 120 
Infection with other viruses. Huh-7.5 cells were seeded onto glass cover slips in 12-121 
well plates and infected for 16 hours with VSV-GFP (kindly provided by Dr. Fanxiu Zhu, 122 
Florida State University) or DENV for 48 hours.   123 
 124 
Plasmid construction and mutagenesis. The HA-ubiquitin plasmid was a gift from Dr. 125 
Fanxiu Zhu (Florida State University). For generation of the K173A CIDEB construct, 126 
mutagenesis was performed using the QuikChange Site-Directed Mutagenesis Kit 127 
(Agilent Technologies, CA) according to manufacturer’s instructions. 128 
 129 
Immunofluorescence Analysis. Cells seeded on slides were fixed in 4% 130 
paraformaldehyde for 10 minutes, followed by three 10- minute washes in phosphate 131 
buffered saline (PBS) at room temperature and blocked in PBTG (PBS containing 0.1% 132 
Triton X-100, 10% normal goat serum, and 1% BSA) at room temperature for 2 hours. 133 
Slides were then incubated with primary antibody at either room temperature for 1 hour 134 
or at 4° C for overnight. Following primary antibody incubation, slides were washed with 135 
PBS for three subsequent 15-minute washes, and then incubated with secondary 136 
antibody for 1 hour at room temperature, followed by three subsequent 15-minute 137 
washes with PBS. Slides were mounted and nuclei stained using VECTASHIELD 138 
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(Vector Labs, CA). Oil Red O (ORO) staining was carried out according to supplier 139 
instructions. 140 
 141 
Western blot. Cells were harvested by trypsinization, pelleting, and subsequent lysis in 142 
1X Laemlli buffer and boiled, or directly lysed in 1x Laemlli buffer and boiled.  143 
 144 
Electroporation of viral RNA. In vitro transcription and electroporation of HCV RNAs 145 
were performed as previously described (29). Viral J6/JFH-1/Gluc and deletion mutants 146 
(ΔE1/E2, Δcore, GNN) RNA were generated in vitro using a MEGAscript T7 kit (Ambion, 147 
TX) and purified by phenol-chloroform extraction. For electroporation, 10ug of RNA was 148 
used for 4x106  cells in a volume of 400ul low serum media in a 4mm cuvette (VWR) 149 
using the Gene Pulser Xcell Electroporation System (Bio-Rad, CA). Medium was 150 
changed four hours post-electroporation. Samples were collected at four hours post 151 
electroporation to control for electroporation efficiency. Samples were collected either 152 
by direct lysis with 1x Laemmli buffer and boiled, or by incubation with trypsin, followed 153 
by pelleting and lysis by boiling in 1x Laemmli buffer for Western blot analysis.The 154 
Jc1/GLuc constructs were provided by Dr. Brett Lindenbach (Yale University).  155 
 156 
Cell Viability Assay. Huh-7.5 cells were seeded into 96-well plates before treatment 157 
with indicated compound for 24 hours. Cells were then assayed in biological triplicate 158 
using the CellTiter-Glo Luminescent cell viability kit according to manufacturer 159 




Co-Immunoprecipitation. Huh-7.5 cells were co-transfected with FLAG-CIDEB or HA-162 
ubiquitin constructs. 18-24 hours after transfection, cells were treated with 10µM MG132, 163 
then washed three times with ice-cold PBS and solubilized with lysis buffer (50 mM 164 
Tris/HCl, pH 7.5, 150 mM NaCl, 1.0 % NP-40, 5 mM EDTA, 5 mM EGTA, 15 mM MgCl2, 165 
60 mM β-glycerophosphate, 0.1 mM sodium orthovanadate, 0.1 mM NaF, 1 mM PMSF, 166 
1× proteinase inhibitor cocktail) for 5 minutes on ice, and then rotated for 1 hour at 4°C. 167 
Cell lysate was centrifuged at 12,000 x g for 10 minutes at 4°C to remove any insoluble 168 
material, and then subjected to IP with EZview anti-Flag M2 or anti-HA affinity beads 169 
(Sigma-Aldrich, MO) according to manufacturer's instructions. The beads were collected 170 
by centrifugation and then washed gently three times with lysis buffer supplemented 171 
with protease inhibitors. Beads and bound protein were boiled in 2× Laemlli buffer and 172 
analyzed via Western blot. 173 
 174 
CIDEB stability assays. To analyze stability of endogenous CIDEB, Huh-7.5 cells were 175 
treated with 2.5µg/mL CHX for the indicated amounts of time before being directly 176 
boiled in 1x Laemmli buffer and analyzed via western blot. For CIDEB mutants, cells 177 
were transfected with the mutant constructs for 18 hours, treated with 2.5µg/mL CHX for 178 
4 hours and analyzed similarly. For proteasome inhibition, cells were treated with 10µM 179 
MG132 for 18 hours. For lipid loading, cells were electroporated with JFH-1 or infected 180 
with JFH-1/AD16 for 24 hours and then incubated in media containing 0µM, 100µM, or 181 




Lipid droplet purification.  Huh-7.5 cells were infected with JFH-1/AD16 for 42 hours 184 
and then treated with 375uM OA for 14 hours. Cells were harvested in ice cold PBS and 185 
stored at -80. Cell pellets were fractionated following a modified previously published 186 
protocol (40). Briefly, cell pellets were dounce homogenized in buffer A (20mM tricine, 187 
250mM sucrose, 1mM PMSF, pH 7.8), overlayed with buffer B (20mM HEPES, 100mM 188 
KCl, 2mM MgCl2, pH 7.4) and ultracentrifuged at 270,000 x g for 1 hour. The floating 189 
crude LD fraction was collected and then centrifuged at 14,000 x g for 10 minutes and 190 
residual underlying liquid and pellet removed. Total LD was then washed with buffer B 191 
four times. Lipids were dissolved with equal amounts chloroform and acetone, and the 192 
resulting protein pellet was resuspended in 1x laemmli buffer. Total protein amount was 193 
measured using the Bio-Rad DC protein assay. For western blot analysis, 15ug of 194 
whole cell lysate and 7.5ug of purified LD proteins were used. 195 
 196 
Lipid droplet stability analysis. Naïve and 60 hour post-JFH-1/AD16 infected Huh-7.5 197 
or naïve Huh-7.5-CIDEB KO cells (single-cell clones #03 and #11) were seeded at low 198 
confluence (10%) onto coverslips in 12-well plates and treated with 375µM OA for 14-20 199 
hours. The cells were then washed three times with PBS, further incubated in fresh, OA-200 
free containing 5.5µM TriC or 40µM PF-429242 for 24 hours before LDs were visualized 201 
using ORO staining.  202 
 203 
VLDL Density Analysis. Naïve and 60 hour post-JFH-1/AD16 infected Huh-7.5 or 204 
naïve Huh-7.5/CIDEB-KO clone #11 cells were incubated in a lipid-rich medium (DMEM 205 
containing 375µM OA, 10% FBS, and non-essential amino acids) for 14 hours, washed 206 
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three times with PBS, then changed into DMEM for 8 hours. Collected supernatant was 207 
fractionated into 11 fractions using a continuous 10-40% iodixanol gradient (77,160 x g 208 
for 17 hours at 4°C). The fractions were analyzed for ApoB content using an ApoB100 209 
detection kit (Mabtech, OH).  210 
 211 
Triglyceride storage and secretion. Huh-7.5 or Huh-7.5/CIDEB-KO clone #11 cells 212 
were incubated in the lipid-rich media for 20 hours, washed three times with PBS, then 213 
incubated in DMEM and collected by scraping in ice-cold PBS and lysed via sonication. 214 
Cell lysate and supernatant were analyzed for TG content using a TG detection kit 215 
(Sigma Aldrich, MO). 216 
 217 
Humanized mouse model sample collection. These methods have been described 218 
previously (41).  219 
 220 
RESULTS 221 
HCV infection downregulates CIDEB in vitro and in vivo. We have previously 222 
observed that JFH-1/HCVcc infection resulted in a lower CIDEB protein level on 223 
western blots without reducing CIDEB mRNA in cultured cells (29). To facilitate single-224 
cell, immunofluorescence-based detection of CIDEB, we generated a stable FLAG-225 
CIDEB-expressing Huh-7.5-based cell line (FLAG-CIDEB CBKO#3) that lacked 226 
endogenous CIDEB expression. Indeed, infection of this cell line and subsequent dual-227 
staining of HCV-infected cells for HCV NS3 and CIDEB revealed a pattern of mutual 228 
exclusivity between HCV expression and CIDEB protein (Fig. 1A, top panel), consistent 229 
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with a HCV-mediated CIDEB downregulation. The uninfected cells exhibited a more 230 
uniform expression pattern of CIDEB (Fig. 1A, second panel) and VSV or Dengue virus 231 
infection of the FLAG-CIDEB CBKO#3 cells did not result in this pattern of exclusion 232 
between infection and CIDEB protein (Fig. 1A, bottom panels). Western blotting 233 
confirmed the downregulation of CIDEB protein by JFH-1, a genotype 2 virus, and its 234 
derivatives (Fig. 1B).We also tested a genotype 3 virus (39), for CIDEB downregulation. 235 
Infection of Huh-7.5.1 cells, a derivative of the Huh-7.5 cell line, with three different 236 
clones of a GT3a virus resulted in virus production with different efficiencies. Higher 237 
levels of core protein (as measured by ELISA) were correlated with a reduction of 238 
endogenous intracellular CIDEB protein level, similar to what was observed in the JFH-239 
1-infected cells (Fig. 1B). The less pronounced downregulation of CIDEB protein by 240 
these GT3 viruses is a likely result of lower infection efficiencies of these isolates, rather 241 
than a genotype specific effect on CIDEB degradation (Fig. 1B). Finally, we investigated 242 
if endogenous human CIDEB is downregulated by HCV infection in vivo. We analyzed 243 
liver samples of human-liver SCID/uPA mice with or without infection by a genotype 1a 244 
HCV derived from human serum (41). As shown in Fig. 1C, liver tissues from HCV 245 
infected mice expressed lower overall CIDEB proteins than those from similarly 246 
transplanted but uninfected animals. Together, these results suggest that CIDEB 247 






CIDEB is normally regulated at the cellular level by ubiquitin-mediated 252 
proteasomal degradation. In addition to HCV infection, the expression level of CIDEB 253 
in liver cells is also regulated by a variety of stimuli (29, 42). In order to understand 254 
whether HCV enhances normal cellular degradation of CIDEB or utilizes a separate, 255 
distinct mechanism, we investigated the cellular mechanism of CIDEB regulation in 256 
uninfected hepatocytes. We performed CHX inhibition experiments to determine the 257 
half-life of the CIDEB protein in uninfected cells. As shown in Fig. 2A, CIDEB is a short-258 
lived protein with an estimated half-life of < 60 minutes, which is near the low end 259 
spectrum of mammalian protein half-lives and well below the average protein turnover 260 
rate (10-20 hours) in human cells reported previously (43). The GAPDH protein was 261 
used as a loading control because it has been reported to have a long half-life of 40-50 262 
hours and thus unlikely to change for the duration of the experiments performed here 263 
(44). To determine whether the rapid turnover of CIDEB is mediated by proteasomes, 264 
we treated the cells with MG132, a proteasome inhibitor, and determined CIDEB protein 265 
level with immunoblotting. An increase of CIDEB level was observed with MG132 266 
treatment in both Huh-7.5 cells and a derivative cell line that harbored a small-hairpin 267 
RNA (shRNA) against the CIDEB mRNA (Fig. 2B), suggesting that proteasomes play a 268 
role in regulating CIDEB protein stability. Because canonical proteasome targeting is 269 
mediated by poly-ubiquitylation of the target protein, we tested whether inhibition of 270 
proteasome-mediated protein degradation results in accumulation of poly-ubiquitinated 271 
CIDEB. Treatment of cells co-transfected with FLAG-CIDEB and HA-ubiquitin with 272 
MG132 resulted in accumulation of poly-ubiquitylated CIDEB, (Fig. 2C), indicating that 273 
the CIDEB protein level is regulated by ubiquitylation and the proteasome. Ubiquitins 274 
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are commonly linked to lysine residues on target proteins. To identify the lysine 275 
residue(s) responsible for CIDEB ubiquitylation, we generated truncation mutants of 276 
CIDEB cDNA where regions containing specific lysine residues were removed (Fig. 2D). 277 
The deletion of amino acids 166 through 195, which contained the two lysine residues, 278 
K172 and K173, significantly stabilized the protein (Fig. 2E). Site-directed mutagenesis 279 
further confirmed that lysine 173 (K173) is important for CIDEB degradation because its 280 
replacement by an alanine residue stabilized the protein (Fig. 2F).  281 
 282 
HCV infection triggers a proteolytic cleavage of CIDEB in a core-dependent 283 
manner. Consistent with our previous report (29), immunoblot analysis of HCVcc 284 
infected Huh-7.5 cells showed reduced CIDEB levels compared to uninfected Huh-7.5 285 
cells. Interestingly, in experiments where the samples were directly lysed in protein 286 
loading buffer and where protein degradation was minimized after cell lysis, the 287 
reduction of CIDEB full-length protein coincided with the appearance of a faster-288 
migrating species that is recognized by the anti-CIDEB antibody (Fig. 3A). This species 289 
was not observed when immunoblot analysis was performed with an IgG control instead 290 
of anti-CIDEB (not shown), indicating that this faster migrating species is a CIDEB 291 
cleavage product and that HCV infection may trigger proteolytic cleavage of CIDEB. 292 
MG132 treatment did not reduce the HCV-activated proteolytic cleavage of CIDEB (Fig. 293 
3B), indicating that the cellular and viral-induced CIDEB downregulation use distinct 294 
mechanisms. A similar band was also observed in the aforementioned FLAG-CIDEB 295 
CBKO#3 cells infected with HCVcc that was detectable by anti-CIDEB antibody (Fig. 3C) 296 
but not by anti-FLAG antibody. Note that the FLAG epitope was fused to the N-terminus 297 
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of CIDEB, which is unstable upon cleavage and cannot be detected with the anti-FLAG 298 
antibody either in IFA (Fig. 1A) or on western blots (data not shown). To identify viral 299 
determinants involved in CIDEB downregulation and cleavage, immunoblot analysis of 300 
CIDEB was performed following electroporation of cells with one of three different 301 
mutant HCV genomes: one with an internal in-frame deletion in the HCV core gene 302 
(Δcore), one with mutations in the active site of the viral polymerase (GNN), and one 303 
with the deletion of the E1E2 genes (ΔE1/E2). While the wildtype genome efficiently 304 
downregulated CIDEB full-length protein and resulted in the appearance of the cleavage 305 
product (Fig. 3D), the Δcore mutant failed to reduce CIDEB level or trigger cleavage 306 
despite expressing similar amounts of the HCV NS3 protease (Fig. 3D). The 307 
polymerase-deficient mutant GNN failed to replicate and did not express detectable 308 
amounts of HCV proteins. It also failed to downregulate CIDEB as expected (Fig. 3D). 309 
On the other hand, the ΔE1/E2 mutant was still able to downregulate CIDEB and to 310 
activate cleavage (Fig. 3E). These results demonstrate that the HCV core, but not the 311 
glycoproteins, is required for CIDEB downregulation via a mechanism independent of 312 
the HCV protease.   313 
 314 
Role of LDs and core’s LD localization in CIDEB downregulation. HCV core 315 
localizes to the surface of LDs in HCV infected cells, which may result in a competition 316 
with other LD-localized proteins such as CIDEB. To address this possibility, we 317 
investigated whether the amount of intracellular lipids and LDs affect CIDEB protein 318 
stability. First, we inhibited LD formation in Huh-7.5 cells using lipid inhibitors and then 319 




pyrrolidinylbenzamide (PF-429242) is a reversible inhibitor of cholesterol and fatty acid 322 
synthesis, acting by blocking SREBP cleavage; Triacsin C (TriC) is an inhibitor of long-323 
chain fatty acid acyl-CoA synthetase. Both compounds inhibited LD formation as 324 
expected without significantly affecting cell viability (Fig. 4A and 4B), and more 325 
importantly, they also effectively reduced CIDEB protein in Huh-7.5 cells (Fig. 4C and 326 
4D). The reduction of CIDEB protein was not due to a decrease in CIDEB mRNA level 327 
upon treatment (Fig. 4E), and we did not detect the putative cleavage product (data not 328 
shown) in these experiments. In the second line of experiments, we augmented 329 
intracellular LD formation by feeding the cells with excess oleic acid (OA) and then 330 
determined if this lipid loading, which significantly increased the number of LDs in Huh-331 
7.5 cells (Fig. 4F), could modulate CIDEB level in HCV-infected cells. Loading the cells 332 
with OA restored the CIDEB protein level in HCV-infected cells to a similar level of that 333 
in uninfected, unloaded cells (Fig. 4G), consistent with the hypothesis that increased LD 334 
availability can counteract the effect of HCV infection on CIDEB level. To directly 335 
address if the localization of HCV core protein to LDs is required for CIDEB 336 
downregulation, we took advantage of a core double proline mutant that reduced its LD 337 
association without significantly affecting its expression level (45). Electroporation of the 338 
full-length HCV genome containing these core mutations (JFHDP) was still capable of 339 
activating the pathway that leads to CIDEB cleavage, but the extent of downregulation 340 
was reduced compared to the wildtype (Fig. 5A). The NS3 expression levels were 341 
comparable, suggesting that core protein and its association with LDs, but not overall 342 
viral protein expression, is correlated with CIDEB downregulation. In addition, the 343 
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reduction of CIDEB protein upon HCV infection was even more pronounced in the LD 344 
fractions (Fig. 5B). Localization of both CIDEB and core onto the surface of the same 345 
LDs could also be detected when we co-expressed these proteins to a level in 346 
uninfected cells (Fig. 5C).  347 
 348 
CIDEB knockout stabilizes LDs in the presence of excess lipids.  A mechanism by 349 
which HCV core may contribute to hepatic steatosis is through the stabilization of 350 
cytoplasmic LDs (25, 26).  Consistent with these reports, we also observed increased 351 
LD stability in hepatoma cells infected with HCV as compared to non-infected (Fig. 6A). 352 
We determined if suppression of CIDEB could similarly affect LD stability. We recently 353 
generated Huh-7.5 cell clones that have the CIDEB gene knocked out using TALEN-354 
based genome editing (29). In the absence of lipid loading, both the CIDEB shRNA and 355 
the CIDEB KO reduced the number of LDs (29). When the cells were fed with lipid-rich 356 
medium that contained oleic acid, however, both parental and KO cells were able to 357 
form LDs (Fig. 6B). To determine if CIDEB KO affects LD stability, we used TriC to 358 
block the synthesis of fatty acids after lipid loading. Under these conditions, the KO cells 359 
contained many more large LDs than the wildtype cells did (Fig. 6C), likely due to the 360 
reduced secretion of the VLDL/LDLs, which can slow down the depletion of their 361 
intracellular reservoir (the cytoplasmic LDs) in the absence of new lipid synthesis. 362 
 363 
CIDEB-knockout in vitro phenocopies the alteration of lipid profiles caused by 364 
HCV infection. Given the involvement of CIDE family proteins in lipid metabolism, we 365 
determined the effect of CIDEB deficiency on the VLDL secretion and intracellular TG 366 
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levels in a human hepatoma cell line. It has previously been shown that Huh-7.5 cells 367 
secrete very little amounts of TG; however, these cells can be used for VLDL studies if 368 
supplemented with exogenous OA in order to first expand the intracellular TG pool (21). 369 
Therefore, we supplied cells with exogenous OA prior to measuring TG secretion. 370 
Compared with wildtype Huh-7.5 cells, the CIDEB KO cells had a reduced level of TG 371 
secretion accompanied by a slight increase of intracellular TG level after lipid loading 372 
(Fig. 7A). In addition, the CIDEB KO cells secreted less ApoB-containing VLDLs (Fig. 373 
7B). Analysis of secreted ApoB particles revealed an overall increase of density of the 374 
ApoB particles secreted from the CIDEB KO cells (Fig. 7C), suggesting a reduction in 375 
intracellular lipidation of ApoB. Overall, the VLDL density profile of ApoB particles 376 
secreted from CIDEB KO cells is similar to the density profiles for ApoB secreted from 377 





In this study, we demonstrate that HCV infection reduces full-length CIDEB protein by 383 
activating a proteolytic cleavage event. This downregulation was independent of HCV 384 
glycoproteins but requires HCV core and may play a role in HCV-induced lipid 385 
accumulation in HCV pathogenesis. 386 
 387 
HCV-induced modulation of CIDEB protein is distinct from the normal ubiquitin-388 
proteasomal regulation of the protein, which has also been shown to modulate CIDEA 389 
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and CIDEC proteins in other cell types (46, 47).  The fine-tuning of CIDE family proteins 390 
by proteasomes may be critical for maintaining normal cell physiology. On one hand, 391 
the CIDE proteins readily induced cell death in a variety of cell types when 392 
overexpressed (27, 30, 31); on the other hand, suboptimal levels of CIDEB can lead to 393 
an imbalance of lipid metabolism. Notably, apoptosis induction likely accounts for a 394 
reported antiviral effect of CIDEB overexpression in cell culture (48), where the authors 395 
concluded that CIDEB’s ability to reduce HCV RNA levels in replicon cells was 396 
correlated with its pro-apoptotic function.    397 
 398 
A specific cleavage in response to a stimulus such as viral infection has not been 399 
reported for any CIDE proteins but appears to be the mechanism of HCV-mediated 400 
downregulation of CIDEB. Previous studies have shown CIDEB KO mice exhibit 401 
increased resistance to diet-induced steatosis and reduced lipogenesis (34). Similarly, 402 
we have observed LD formation being impaired in uninfected human hepatoma cells 403 
when CIDEB expression is reduced by shRNA or eliminated by gene knockout (29). 404 
Upon HCV infection which increases lipogenesis (12, 14, 23), however, CIDEB 405 
depletion causes altered VLDL profiles and leads to intracellular lipid accumulation. 406 
Similarly, when cells were fed with excess lipids, suppression of CIDEB stabilized 407 
cytoplasmic LDs. The observation that genetic ablation led to perturbations of the lipid 408 
secretion pathway similar to those caused by HCV infection suggest a connection 409 
between CIDEB modulation and lipid regulation in infected cells. Consistent with this 410 
hypothesis, HCV-induced CIDEB downregulation was observed in cultured cells 411 
infected with a genotype 3 virus as well as in infected liver tissues of a HCV mouse 412 
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model. The in vivo data is consistent with a previous report showing that transgenic 413 
expression of HCV proteins in mice led to a reduction of CIDEB protein (31), even 414 
though the cleavage product was not detectable from the in vivo samples, which could 415 
be due to the labile nature of the protein, especially considering the fixing and 416 
processing necessary for the live tissues. Combined with a growing body of evidence 417 
supporting the function of the CIDE proteins in lipid regulation and the reported role of 418 
HCV core in virus-induced steatosis, our results support a model (Fig. 8) where chronic 419 
HCV infection of human hepatocytes results in sustained reduction of CIDEB protein, 420 
which in turn contributes to hepatic lipid dysregulation and steatosis. 421 
 422 
Localization of HCV core to the surface of LDs is important for HCV assembly (3), and 423 
colocalization of a LD-targeted cellular factor, TIP47, with NS5A and core on LDs may 424 
be required for HCV replication and release (49). On the other hand, the extensive 425 
coating of the LD surface by HCV core protein in the infected hepatocytes can lead to 426 
displacement of native LD proteins such as CIDEB and perilipins. Such a competition 427 
has been shown to play a role in the downregulation of perilipin 2 (PLIN2) protein, also 428 
known as adipocyte differentiation-related protein (ADRP). The dissociation of ADRP 429 
protein from LDs, as a result of core competition, led to reduced stability of ADRP (50), 430 
presumably due to increased exposure to protease(s). Our results suggest a role of 431 
HCV core’s LD localization in CIDEB downregulation, consistent with such a 432 
competition/displacement model that is distinct from HCV NS3/4A-mediated cleavage of 433 
critical antiviral signaling proteins (51, 52). Of note, no specific interaction between 434 




The displacement of CIDEB from the LD surface may expose the protein to a protease 437 
that normally does not have access to CIDEB. Alternatively, the presence of HCV core 438 
during infection may activate a protease that can cleave CIDEB. Preliminary 439 
experiments testing different classes of protease inhibitors, including Calpain and 440 
caspase inhibitors, yielded inconclusive results so far. The Δcore mutant genome 441 
expresses both NS2 and the NS3/4A proteases encoded by HCV but failed to 442 
downregulate CIDEB protein or trigger the proteolytic cleavage, suggesting the 443 
involvement of cellular, rather than viral proteases.  The identification of the specific 444 
protease(s) that is responsible for cleaving CIDEB in a HCV-dependent manner can 445 
provide promising candidates for targeted interventions of lipid dysregulation.  446 
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Figure Legends 627 
 628 
Fig. 1. HCV infection downregulates CIDEB in vitro and in vivo. (A) 629 
Immunofluorescence staining of viral proteins and CIDEB. Huh-7.5-based CIDEB-KO 630 
cells (clone #3) stably expressing FLAG-CIDEB were infected with a high-titer JFH-1 631 
(HCV) variant, JFH-1/AD16 (genotype 2), for 3 days before co-staining for FLAG and 632 
HCV NS3. FLAG-CIDEB CBKO#3 cells were infected with VSV-GFP for 16 hours, 633 
stained for FLAG-CIDEB, and analyzed for co-expression of FLAG-CIDEB and GFP. 634 
FLAG-CIDEB CBKO#3 cells were infected with DENV for 48 hours, and co-stained for 635 
FLAG-CIDEB and DENV NS3. (B) Immunoblot of CIDEB in genotype 2 (top panels) or 636 
genotype 3 (bottom panels)-infected cells. Cells were infected for 3 days with various 637 
genotype 2a virus before analysis by western blot or for 8 days with various genotype 638 
3a-based (S310) clones or the S310/JFH-1 chimera. On day 8 post-infection, core 639 
protein was measured from the supernatants by HCV core-specific ELISA, and cell 640 
lysates were analyzed by western blot for CIDEB. Beta-actin was included as a loading 641 
control. (C) CIDEB protein levels in HCV-infected uPA/SCID humanized mouse model. 642 
Liver tissue lysates from primary human hepatocytes (PHH)-transplanted uPA/SCID 643 
mice, either uninfected (n=5) or HCV infected (n=5), were subjected to western blot to 644 
measure CIDEB protein levels. Data from individual mice are plotted as CIDEB protein 645 
normalized to GAPDH protein (control). Quantification of band intensity was performed 646 
using the ImageJ software (National Institutes of Health). HCV-infected versus non-647 
infected humanized mice showed statistically significant levels of CIDEB protein (p = 648 




Fig. 2. Endogenous CIDEB is a short-lived protein that is post-translationally regulated 651 
via the ubiquitin-proteasome pathway. (A) Cells were treated with the protein synthesis 652 
inhibitor CHX for 0, 1, 2, or 3 hours, then lysed and analyzed by western blot for CIDEB 653 
protein levels. GAPDH was included as a loading control. (B) Treatment with the 654 
proteasome inhibitor MG132 blocked CIDEB degradation in both wildtype cells and in 655 
cells harboring a lentivirus encoding shRNA targeting CIDEB mRNA. (C) Analysis of 656 
CIDEB ubiquitination. Cells were co-transfected with FLAG-CIDEB or a FLAG-control 657 
protein (Prp31c) and HA-ubiquitin constructs, followed by MG132 treatment, co-658 
immunoprecipitation with anti-FLAG beads, and western blot. (D) A schematic of FLAG-659 
CIDEB deletion constructs used for stability analysis. (E) Stability of CIDEB deletion 660 
mutants. Cells were transfected with various FLAG-CIDEB-encoding constructs 661 
(represented in D) and subsequently treated with CHX, 24 hours post transfection, for 4 662 
hours, before immunoblot analysis using FLAG-specific antibody. (F) The point mutation 663 
K173A enhanced CIDEB stability. Cells transfected with wildtype or K173A CIDEB 664 
mutant cDNA were treated with CHX, collected at the indicated times, and analyzed 665 
similar to (A). 666 
 667 
Fig. 3. HCV-infected cells exhibit lower levels of CIDEB protein, likely through a 668 
proteolytic cleavage event. (A) Effect of HCV infection on endogenous CIDEB protein. 669 
Western blot analysis of Huh-7.5 cells infected with JFH-1/AD16 for 3 days revealed a 670 
faster-migrating band recognized by the CIDEB antibody, in addition to the full-length 671 
product. The asterisk indicates a degradation product occasionally seen from uninfected 672 
Huh-7.5 cells. (B) Effect of proteasome inhibition on CIDEB protein levels in HCV 673 
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infected cells. Huh-7.5 cells were infected with JFH-1/AD16 for 48 hours, then treated 674 
with MG132 for 18 hours before analysis by western blot. A longer exposure of GAPDH, 675 
CIDEB and the CIDEB cleavage product are shown to the right. (C) Effect of HCV 676 
infection on N-terminally FLAG-tagged CIDEB. Western blot analysis of CIDEB-KO cells 677 
(clone #3) stably expressing FLAG-CIDEB and electroporated with JFH-1 for 3 days. 678 
FLAG-CIDEB was detected by anti-CIDEB antibody. (D) Western blot analysis of 679 
endogenous CIDEB and NS3 levels in Huh-7.5 cells with various HCV RNAs. Cells 680 
were electroporated with 10µg of RNA generated from either wildtype or mutant 681 
genomes and then analyzed 48 hours later for their ability to downregulate CIDEB. 682 
Δcore: a Jc1/GLuc variant lacking the intact HCV capsid protein; GNN: a Jc1/GLuc 683 
variant harboring a replication-deficient replicase. (E) Similar analysis of endogenous 684 
CIDEB and NS3 levels in Huh-7.5 cells 48 hours after cells were electroporated with 685 
10µg of RNA generated from either wildtype JFH-1 or ΔE1/E2-JFH-1, a viral-encoding 686 
construct lacking the two HCV envelope proteins.  687 
 688 
Fig. 4. Intracellular lipid abundance affects CIDEB protein stability. (A) Effect of two 689 
structurally distinct lipid droplet inhibitors, PF-429242, a reversible inhibitor of 690 
cholesterol synthesis and Triacsin C, an inhibitor of long-chain fatty acid acyl-CoA 691 
synthetase, on LDs in Huh-7.5 cells. Cells were treated with 40µM PF-429242 or 5.5µM 692 
of TriC for 24 hours before staining with ORO. (B) Cell viability was measured after 24 693 
hours treatment with the indicated compound. (C and D) Western blot analysis of 694 
CIDEB protein levels in Huh-7.5 cells treated with PF-429242 or TriC for 24 hours. 695 
Quantification of CIDEB protein levels on western blot by ImageJ analysis (analyzed 696 
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from biological triplicates). Ku80 was used as a loading control. (E) 24 hour treatment of 697 
Huh-7.5 cells with PF-429242 or TriC do not significantly alter CIDEB mRNA levels. (F 698 
and G) Effect of exogenous lipid loading on CIDEB protein in infected cells. Uninfected 699 
or (24 hour) JFH-1/AD16 infected Huh-7.5 cells were treated with 100µM OA for 20 700 
hours before being fixed for ORO staining or lysed for western blot analysis.  701 
 702 
Fig. 5. (A) Effect of a JFH-1 core mutant deficient in LD-targeting on CIDEB cleavage. 703 
Western blot analysis of Huh-7.5 cells was performed 48 hours after electroporation of 704 
cells with 10µg of JFH-1 or JFH-DP RNA. (B) Localization of endogenous CIDEB and 705 
HCV core after HCV infection assayed by LD fractionation. 15ug of whole cell lysate 706 
(WCL) and 7.5ug of purified LD-associated proteins were analyzed by WB. (C) Co-707 
localization of exogenously overexpressed FLAG-tagged CIDEB and HCV core protein 708 
on lipid droplets. 709 
 710 
Fig. 6. CIDEB modulates LD stability. (A) LD stability in naïve or JFH-1/AD16 infected 711 
Huh-7.5 cells. Cells were incubated in lipid-rich medium for 14 hours, washed with PBS 712 
and cultured in DMEM with 5.5uM TriC for 24 hours before staining with ORO (red, 713 
100x) and DAPI (blue), or anti-NS3 (green, 40x) and DAPI. (B) Formation of LDs in 714 
Huh-7.5 or Huh-7.5 CIDEB-KO after lipid loading. Cells were incubated in the lipid-rich 715 
medium for 20 hours, washed with PBS and stained for LDs using ORO (red, 100x). (C) 716 
LD stability in wildtype and CIDEB KO cells. After lipid loading as above, cells were 717 
cultured in DMEM with or without 5.5 µM of TriC for 24 hours and then stained for LDs 718 
30 
 
using ORO (red, 100x).Panels 1, 2, and 3 are separate frames. DAPI (blue) was used 719 
as a counterstain. 720 
 721 
Fig. 7. Knockout of CIDEB in human hepatoma cells results in altered VLDL secretion 722 
and TG storage. (A) Secreted and intracellular TG in Huh-7.5 or Huh-7.5 CIDEB-KO 723 
(clone #11) cells. Cells were cultured in a lipid-rich medium (supplemented with 375µM 724 
OA) for 20 hours, washed with PBS and then either collected for lysate or further 725 
incubated in fresh DMEM for 2 hours for supernatant collection. Both lysate and 726 
supernatant were analyzed for TG contents. (B) Analysis of secreted and intracellular 727 
ApoB levels. Huh-7.5 cells or or Huh-7.5 CIDEB-KO (clone #11) cells were cultured in a 728 
lipid-rich medium (supplemented with 375µM OA) for 14 hours, washed with PBS and 729 
then further incubated in fresh DMEM for 8 hours for supernatant collection. (C) Lipid 730 
density profile of secreted ApoB-associated VLDL particles. Fractions of the 731 
supernatant collected above were analyzed for amount of ApoB protein in each fraction. 732 
Distribution of ApoB-containing particles of different densities are quantified and plotted. 733 
Data from three replicate experiments are shown. (D) Lipid density profile of secreted 734 
ApoB-associated VLDL particles in HCV infected cells. Naïve and 60 hour post-JFH-735 
1/AD16 infected Huh-7.5 cells were cultured in a lipid-rich medium (supplemented with 736 
375µM OA) for 14 hours, washed with PBS and then further incubated in fresh DMEM 737 
for 8 hours for supernatant collection. Fractions of the supernatant collected above were 738 
analyzed for amount of ApoB protein in each fraction. Distribution of ApoB-containing 739 
particles of different densities are quantified and plotted. Data from two biological 740 




Fig. 8. Potential mechanism for HCV-mediated CIDEB downregulation. CIDEB protein 743 
levels are normally regulated by the ubiquitin-proteasome pathway (A). In the infected 744 
cells, HCV core is trafficked onto LDs (B), which may result in competitive displacement 745 
of CIDEB off the LD surface (C), exposing CIDEB to a protease. Reduced level of 746 
CIDEB results in altered VLDL lipid profile (D), through a mechanism involving the 747 
reported CIDEB – ApoB interaction (E) (34).  748 
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